京都大学：授予艾利iPS细胞许可：心肌细胞的制造方法
京都大学创业：“ Myoridge”
4月19日，在美国与Avery Therapeutics（Avery）签订了非排他性许可协议。
美国Avery Therapeutics（Avery）：
美国的Avery Therapeutics（Avery）是一家使用iPS细胞衍生的心肌细胞开发再生医学相关产品的公司。
艾利（Avery）正在为患有心血管疾病的患者开发先进的治疗方法。
主要开发渠道
它是一种正在开发的可再生药物产品MyCardia，用于治疗慢性心力衰竭。
iPS单元许可
Avery将获得京都大学和Myoridge拥有的诱导iPS细胞衍生的心肌细胞分化方法的许可。
该合同是
作为产生iPS细胞来源的心肌细胞的方法，
向海外提供临床应用技术，
这是第一份许可协议。
Avery在北美制造和销售
使用差异诱导法的产品，
在北美的制造，开发和销售
获得非排他性权利。
目前，艾利的产品正处于非临床试验阶段。
Myoridge的基本技术
除了京都大学许可的指导方法外，我们还有以下基本技术。
iPS细胞干细胞和
中胚层来源的细胞
心肌细胞
间充质干细胞
血细胞系等
Myoridge具有“制造的基本技术”。
据说将来它将通过向世界传播高度原始的基础技术来促进再生医学的传播。
https://jp.techcrunch.com/2021/04/19/myoridge-avery-therapeutics/
April 19, 2021
Myoridge. Co. Ltd.
Myoridge completes out-license agreement with United States-based regenerative medicine company Avery Therapeutics for iPS cell-derived cardiomyocytes
Myoridge Co. Ltd. (President: Naohiro Makita)
has signed a license agreement with Avery Therapeutics, Inc. (“Avery”), a company based in Arizona that develops regenerative medicine products using iPS cell-derived cardiomyocytes.
Myoridge provides to Avery
a non-exclusive license for the method of inducing differentiation of iPS cell-derived cardiomyocytes owned by Myoridge and licensed from Kyoto University.
Under this agreement,
Avery will use the differentiation induction method to generate cells that will be used in Avery’s products, which are currently in the pre-clinical research stage.
This Agreement gives Avery a non-exclusive right to manufacture,
develop and sell products using this differentiation induction method in North America.
This agreement
is the first published license agreement for the manufacture of iPS cell-derived cardiomyocytes technology owned by Kyoto University,
which aims to provide technology for clinical application to companies internationally.
Myoridge
has basic technology for producing stem cells such as iPS cells and mesoderm-derived cells (cardiomyocytes, mesenchymal stem cells, blood cell lines, etc.)
and has licensed the differentiation induction method from Kyoto University.
Myoridge
will continue to contribute to the spread of regenerative medicine by providing highly unique basic technologies to the world.
About Myoridge
A start-up company established based on the research results of Kyoto University, which induces differentiation of pluripotent cells into differentiated cells, including myocardial cells by suspension culture without expensive proteins by using low-molecular-weight compounds.
This differentiation induction method is licensed from Kyoto University.
In addition to selling iPS cell-derived cardiomyocytes utilizing the technology, we offer custom-made, medium development support and manufacturing process development
support using our own low-molecular-weight compound database and patent-pending medium component search technology.
http://myoridge.co.jp/wp/wp-content/uploads/20210301_News_Release_Myoridge_Licence_Agreement.pdf
Myoridge Co. Ltd.